Xenon Pharmaceuticals Inc.

XENE

Xenon Pharmaceuticals Inc.

XENE

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-05Shares Purchased (TTM):0Shares Sold (TTM):105,146

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:94,731,575Shares Outstanding:87,345,717Institutional Ownership Pct.:108.46%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	120	546	199	105	135	117	143	88	137	59	149	100
Marketable Securities Current	811	549	350	358	352	433	484	566	585	641	489	427
Accounts And Other Receivables Net Current	-	-	-	-	-	9	-	-	-	-	-	-
Other Receivables Net Current	2	1	1	1	1	-	1	-	-	-	-	-
Accounts Receivable Net Current	-	-	-	-	-	-	1	1	1	1	1	1
Prepaid Expense And Other Assets Current	14	11	10	17	12	7	7	5	6	7	6	4
Assets Current	946	1,107	561	480	500	566	635	660	728	707	645	531
Marketable Securities Noncurrent	314	245	37	93	137	141	127	149	129	186	293	112
Operating Lease Right Of Use Asset	5	6	7	7	7	8	8	8	9	9	9	9
Property Plant And Equipment Net	8	8	9	9	9	10	10	10	10	9	10	10
Deferred Income Tax Assets Net	14	12	13	12	11	11	10	1	1	0	1	1
Prepaid Expense Noncurrent	8	8	7	7	9	8	7	7	7	7	7	7
Assets	1,296	1,387	633	608	674	743	798	836	884	919	965	671
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	44	38	40	37	32	31	34	28	30	21	26	23
Operating Lease Liability Current	1	2	2	1	1	1	1	1	1	1	1	1
Liabilities Current	45	40	42	38	33	32	36	30	31	22	27	25
Operating Lease Liability Noncurrent	5	6	6	7	7	7	8	8	9	9	10	10
Other Liabilities Noncurrent	3	3	3	3	-	-	0	-	-	-	-	-
Liabilities	53	49	51	48	40	39	43	38	40	31	37	35
Stockholders Equity
Common Stock Value	2,427	2,422	1,599	1,475	1,469	1,461	1,457	1,442	1,440	1,439	1,436	1,122
Additional Paid In Capital Common Stock	277	265	228	224	214	208	199	188	177	164	157	138
Retained Earnings Accumulated Deficit	-1,458	-1,348	-1,245	-1,140	-1,049	-965	-899	-834	-771	-713	-665	-620
Accumulated Other Comprehensive Income Loss Net Of…	-3	-1	0	0	0	-1	-2	1	-2	-2	-0	-3
Stockholders Equity	1,242	1,338	582	560	634	704	755	798	844	888	928	637
Liabilities And Stockholders Equity	1,296	1,387	633	608	674	743	798	836	884	919	965	671
Common Stock Shares Issued	97	97	80	77	77	77	76	76	76	75	75	65
Shares Outstanding	97	97	80	77	77	77	76	76	76	75	75	65

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.27%	6.68%	16.82%	-	-	-	-	-	-	-	-	-
2025	-11.74%	-7.22%	-14.92%	14.95%	16.12%	22.90%	8.75%	9.05%	1.56%	22.31%	32.90%	21.08%
2024	-10.40%	-8.24%	3.46%	-1.63%	-5.75%	1.76%	-1.54%	-6.64%	-7.86%	-7.75%	-8.35%	-20.93%
2023	-	-	-	12.07%	-3.64%	-12.92%	14.46%	43.27%	41.96%	-6.78%	-15.51%	-15.68%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	21.02	27.79	13.42	12.52	15.14	17.66	17.85	22.21	23.27	31.82	23.65	21.46
Quick Ratio	20.71	27.53	13.17	12.08	14.79	17.43	17.66	22.06	23.09	31.52	23.43	21.32
Working Capital	900.86M	1.07B	518.86M	441.80M	467.21M	533.51M	599.67M	629.94M	696.80M	684.98M	617.69M	506.26M
Leverage & Debt
Debt to Equity	0.04	0.04	0.09	0.09	0.06	0.06	0.06	0.05	0.05	0.04	0.04	0.05
Debt Ratio	0.04	0.04	0.08	0.08	0.06	0.05	0.05	0.05	0.05	0.03	0.04	0.05
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Receivables Turnover TTM	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-4.11	-4.39	-4.36	-3.87	-3.52	-3.20	-3.01	-2.74	-2.56	-2.43	-2.73	-2.66
Free Cash Flow Per Share TTM	-3.40	-3.52	-3.53	-3.20	-2.93	-2.54	-2.37	-2.11	-2.11	-2.15	-2.34	-2.36
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-4,974.27%	-4,543.73%	-4,241.60%	-3,906.60%	-	-	-	-	-	-
Net Profit Margin TTM	-	-	-4,612.13%	-4,084.45%	-3,709.71%	-3,352.61%	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%
Net Income Growth (1Y)	47.07%	52.38%	47.62%	43.56%	39.77%	33.32%	28.48%	21.70%	21.35%	27.66%	45.48%	53.77%
EPS Growth (1Y)	16.57%	37.28%	45.09%	41.16%	37.50%	31.47%	10.32%	3.08%	2.90%	8.13%	31.68%	52.52%
Valuation Metrics
P/E TTM	-14.69	-13.26	-10.27	-10.39	-8.88	-10.50	-13.03	-14.38	-15.21	-17.71	-16.89	-12.86
P/B TTM	4.84	3.80	6.11	5.69	3.90	3.75	4.04	3.85	3.59	3.76	3.32	3.54
P/S TTM	-	-	473.62	424.24	329.50	352.00	-	-	-	-	-	-
Market Cap	6.01B	5.08B	3.55B	3.18B	2.47B	2.64B	3.05B	3.07B	3.03B	3.34B	3.08B	2.25B
Enterprise Value	5.89B	4.53B	3.35B	3.08B	2.34B	2.52B	2.91B	2.98B	2.89B	3.28B	2.93B	2.16B
Calculated Values
Free Cash Flow TTM	-338.53M	-307.25M	-279.92M	-253.29M	-231.51M	-199.78M	-184.46M	-164.78M	-163.80M	-166.49M	-156.73M	-155.73M
Net Debt	-119.53M	-545.87M	-199.16M	-104.51M	-135.38M	-116.66M	-142.71M	-87.62M	-136.73M	-58.90M	-148.64M	-99.57M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-05Sale

Owner: Cannon, Gillian

Title: -

Shares: 1,190

Price/Share: $53.14

Value: $63,236.60

Shares Owned: 1,455

Relationship: Director

Ownership: Direct

2026-06-05Sale

Owner: Patou, Gary

Title: -

Shares: 1,322

Price/Share: $53.14

Value: $70,251.08

Shares Owned: 24,896

Relationship: Director

Ownership: Direct

2026-03-13Sale

Owner: Kenney, Christopher John

Title: Chief Medical Officer

Shares: 1,410

Price/Share: $55.23

Value: $77,874.30

Shares Owned: 7,069

Relationship: Officer

Ownership: Direct

2026-03-13Sale

Owner: Mortimer, Ian

Title: PRESIDENT & CEO

Shares: 7,308

Price/Share: $55.23

Value: $403,620.84

Shares Owned: 19,923

Relationship: Director,Officer

Ownership: Direct

2026-03-13Sale

Owner: Difabio, Andrea

Title: Chief Legal Officer

Shares: 1,342

Price/Share: $55.23

Value: $74,118.66

Shares Owned: 7,301

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-05	Cannon, Gillian	Director	-	Direct	Sale	1,190	53.14	$63,236.60	1,455	4
2026-06-05	Patou, Gary	Director	-	Direct	Sale	1,322	53.14	$70,251.08	24,896	4
2026-03-13	Kenney, Christopher John	Officer	Chief Medical Officer	Direct	Sale	1,410	55.23	$77,874.30	7,069	4
2026-03-13	Mortimer, Ian	Director,Officer	PRESIDENT & CEO	Direct	Sale	7,308	55.23	$403,620.84	19,923	4
2026-03-13	Difabio, Andrea	Officer	Chief Legal Officer	Direct	Sale	1,342	55.23	$74,118.66	7,301	4
2026-03-10	Difabio, Andrea	Officer	Chief Legal Officer	Direct	Sale	2,607	60.11	$156,706.77	4,893	4
2026-03-10	Mortimer, Ian	Director,Officer	PRESIDENT & CEO	Direct	Sale	11,269	60.11	$677,379.59	14,731	4
2026-03-10	Kenney, Christopher John	Officer	Chief Medical Officer	Direct	Sale	2,771	60.11	$166,564.81	4,729	4
2026-01-02	Mortimer, Ian	Director,Officer	PRESIDENT & CEO	Direct	Sale	40,000	44.66	$1,786,400.00	6,000	4
2025-12-08	Mortimer, Ian	Director,Officer	PRESIDENT & CEO	Direct	Sale	10,830	45.96	$497,746.80	6,000	4
2025-11-28	Mortimer, Ian	Director,Officer	PRESIDENT & CEO	Direct	Sale	97	45.01	$4,365.97	31,205	4
2025-10-01	Mortimer, Ian	Director,Officer	PRESIDENT, CEO & INTERIM CFO	Direct	Sale	25,000	40.16	$1,004,000.00	31,302	4
2025-06-05	Gannon, Steven	Director	-	Direct	Sale	3	30.48	$91.44	7,141	4
2025-01-27	Mortimer, Ian	Director,Officer	PRESIDENT & CEO	Direct	Sale	16,315	40.76	$664,999.40	31,302	4
2024-12-18	Aulin, Sherry	Officer	Chief Financial Officer	Direct	Sale	18,709	41.21	$770,997.89	0	4
2024-11-22	Patou, Gary	Director	-	Direct	Sale	4,891	41.08	$200,922.28	23,573	4
2024-03-08	Garofalo, Elizabeth A.	Director	-	Direct	Sale	2,092	45.69	$95,583.48	0	4
2024-03-07	Gannon, Steven	Director	-	Direct	Sale	13,000	46.30	$601,900.00	2,000	4
2024-03-07	Robin, Sherrington	Officer	EVP, Strategy & Innovation	Direct	Sale	7,137	46.22	$329,872.14	8,398	4
2023-12-14	Patou, Gary	Director	-	Indirect	Sale	7,598	41.05	$311,897.90	4,902	4/A
2023-12-13	Patou, Gary	Director	-	Direct	Sale	11,380	39.29	$447,120.20	23,573	4
2023-08-24	Svoronos, Dawn	Director	-	Direct	Sale	25,000	38.70	$967,500.00	25,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

108.46%

Inst. Shares: 94,731,575

Shares Outstanding: 87,345,717

2025-12-31

102.80%

Inst. Shares: 81,470,006

Shares Outstanding: 79,253,751

2025-09-30

104.37%

Inst. Shares: 82,707,795

Shares Outstanding: 79,247,976

2025-06-30

103.54%

Inst. Shares: 81,748,375

Shares Outstanding: 78,953,445

2025-03-31

93.91%

Inst. Shares: 73,892,013

Shares Outstanding: 78,687,503

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	94,731,575	87,345,717	108.46%
2025-12-31	81,470,006	79,253,751	102.80%
2025-09-30	82,707,795	79,247,976	104.37%
2025-06-30	81,748,375	78,953,445	103.54%
2025-03-31	73,892,013	78,687,503	93.91%
2024-12-31	72,550,847	77,894,643	93.14%
2024-09-30	70,989,296	77,926,205	91.10%
2024-06-30	70,314,381	77,671,128	90.53%
2024-03-31	68,312,034	77,594,599	88.04%
2023-12-31	67,747,851	66,889,005	101.28%
2023-09-30	57,782,956	66,002,163	87.55%
2023-06-30	57,062,287	65,861,138	86.64%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Xenon Pharmaceuticals Inc. (XENE) — SEC Financial Statements & Analysis

Xenon Pharmaceuticals Inc. (XENE) is a pharmaceutical preparations company, incorporated in A1. Xenon Pharmaceuticals Inc. trades on Nasdaq as: XENE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Xenon Pharmaceuticals Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.04x, a Price-to-Sales (P/S) ratio of 473.62x (TTM), a Price-to-Book (P/B) ratio of 4.84x (TTM), at a market cap of $6.01B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.04x
P/S TTM: 473.62x
P/B TTM: 4.84x
Market Cap: $6.01B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Xenon Pharmaceuticals Inc. in?

Xenon Pharmaceuticals Inc. (XENE) operates in the Pharmaceutical Preparations industry.

What is XENE's market cap?

Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $6.01B as of 2026-06-30.

What exchange does XENE trade on?

Xenon Pharmaceuticals Inc. (XENE) trades on the Nasdaq.

Where is Xenon Pharmaceuticals Inc. incorporated?

Xenon Pharmaceuticals Inc. is incorporated in British Columbia, Canada.